Xetrab-RD Capsule SR is a combination medication containing Domperidone 30mg and Rabeprazole 20mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting healing of acid-related mucosal damage and providing symptomatic relief from gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release formulation ensures a prolonged therapeutic effect, improving patient compliance and symptom control. Xetrab-RD is indicated for the treatment of acid peptic disorders accompanied by delayed gastric emptying, including GERD with associated dyspeptic symptoms. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, and caution is advised in patients with hepatic or renal impairment. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination therapy offers a synergistic approach by addressing both acid suppression and motility enhancement, optimizing treatment outcomes in upper gastrointestinal conditions.